Gilead opting against IDE397 is still good news for Ideaya.
ApexOnco Front Page
Recent articles
Progression-free and overall survival data from Companion-002 are due this quarter.
Five years after settling, GSK is again accused of breaching the Jemperli deal.
Meanwhile, Zai Lab faces delays in its pivotal DLL3 trial.
The cash-strapped biotech adds Car-T projects but tries to avoid a lawsuit.
The company adds royalty aggregation to its R&D business.
And AbbVie and Genmab scoop their ASH presentation with new data.
But Enhertu is coming.
